Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

41 results about "Placental tissue" patented technology

Sterile human placental allografts and methods of making thereof

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.
Owner:BIOSTEM TECHNOLOGIES INC

Sterile human placental allografts having a plurality of slits, openings, and / or fenestrations formed thereon

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.
Owner:BIOSTEM TECHNOLOGIES INC

Sterile human placental allografts having a plurality of slits, openings, and / or fenestrations formed thereon

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.
Owner:BIOSTEM TECHNOLOGIES INC

Step-by-step targeted placenta trophoblast micro-nano robot as well as preparation method and application thereof

PendingCN120037406AAntipyreticAnalgesicsCells/microLTrophoblast
The invention discloses a step-by-step targeting placenta trophoblast micro-nano robot as well as a preparation method and application thereof. The micro-nano robot comprises a yeast cell wall of a bag-shaped structure, bio-enzyme unevenly distributed on the surface of the yeast cell wall and targeted placenta trophoblast drug-loaded nanoparticles located in the yeast cell wall. The surfaces of the targeted placenta trophoblast drug-loaded nanoparticles are connected with placenta-like chondroitin sulfate A binding polypeptides. Inflammation placenta tissue can be targeted through macrophages, the medicine is accurately delivered to placenta trophoblastic cells through the medicine-carrying nano-particles connected with the targeting peptide, step-by-step accurate targeting is achieved, the medicine does not penetrate through the placenta barrier to reach the body of a fetus, and high biological safety is achieved for pregnancy administration.
Owner:THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY

Genetically engineered placental mucosal-associated invariant t (MAIT) cells and uses thereof

This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.
Owner:PLURI BIOTECH LTD

Placental tissue grafts and improved methods of preparing and using the same

Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located on top of and within the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high levels of laminin-5, a cell adhesion bio-active factor shown to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.
Owner:MIMEDX GROUP INC

Genetically engineered placental mucosa related constant T (MAIT) cells and uses thereof

One major aspect of the invention relates to a cell composition comprising a population of engineered mucosa-related constant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.
Owner:PLURI BIOTECH LTD

Method and composition for hypothermic storage of placental tissue

A tissue storage solution includes hypothermic storage compositions and methods. The hypothermic storage composition includes media containing Dulbecco's modified Eagle's medium (DMEM) and albumin. A method of hypothermically storing tissue includes storing such tissue in a storage medium including DMEM and albumin. A method for wound or defect treatment includes applying tissue, stored in a hypothermic storage medium containing DMEM and albumin, to the site of such wound or defect.
Owner:PRIME MERGER SUB LLC

Reinforced placental tissue grafts and methods of making and using the same

Described herein are tissue grafts derived from the placental tissue that are reinforced with at least one biocompatible mesh. The tissue grafts possess good adhesion to biological tissues and are useful in wound healing applications. Also described herein are methods for making and using the tissue grafts.
Owner:MIMEDX GROUP INC

Method and composition for hypothermic storage of placental tissue

A tissue storage solution includes hypothermic storage compositions and methods. The hypothermic storage composition includes media containing Dulbecco's modified Eagle's medium (DMEM) and albumin. A method of hypothermically storing tissue includes storing such tissue in a storage medium including DMEM and albumin. A method for wound or defect treatment includes applying tissue, stored in a hypothermic storage medium containing DMEM and albumin, to the site of such wound or defect.
Owner:PRIME MERGER SUB LLC

Placental tissue compositions and methods

ActiveUS12247225B2ObstetricsPhysiology
Disclosed herein are methods and compositions of decellularized preterm placental tissue. Compositions comprise decellularized regenerative tissue derived from animal placentas that are harvested preterm, i.e., before the completion of the normal duration of gestation. Preterm placental tissue may contain a high level of growth factors and other beneficial components that aid in tissue regeneration and healing.
Owner:ELUTIA INC

Sterile human placental allografts having a plurality of slits, openings, and / or fenestrations formed thereon

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.
Owner:BIOSTEM TECHNOLOGIES INC

A method and system for predicting adverse pregnancy outcomes of preeclampsia by fusing placental microenvironment image features and serum biomarkers

The present application relates to the technical field of medical data fusion processing, and discloses a method and system for predicting adverse pregnancy outcomes of preeclampsia by fusing placental microenvironment image features and serum biomarkers, wherein the method comprises: obtaining digital whole field image of placental tissue section and serum biomarker detection data at the same period; constructing a multi-modal sample data set; extracting multi-scale structure features of placental microenvironment; constructing serum biomarker discriminant features; dynamically fusing placental image features and serum marker features; constructing a prediction model for adverse pregnancy outcomes of preeclampsia and outputting a prediction probability. Compared with the prior art which only relies on single image information or single serum biomarker for risk assessment, it is difficult to realize stable prediction of the coordinated changes of placental microenvironment abnormalities and biochemical abnormalities. Due to the multi-scale image structure analysis, the model generalization ability for predicting adverse pregnancy outcomes of preeclampsia is improved.
Owner:THE SEVENTH MEDICAL CENTER OF PLA GENERAL HOSPITAL

Placenta tissue grinding and inoculating device

The utility model provides a placenta tissue grinding and inoculating device, which relates to the field of placenta grinding, and comprises a container bottle for placing placenta tissues; the grinding shell is rotationally connected to the open end of the container bottle, and a cavity of the grinding shell communicates with a cavity of the container bottle; a first cutter body and a second cutter body are arranged in the grinding shell, the first cutter body and the second cutter body rotate relatively, and a grinding space is formed between the first cutter body and the second cutter body; an adjusting piece for adjusting the size of the cut placenta tissue is arranged in the grinding shell, and the adjusting piece is located on the side, away from the container bottle, of the second cutter body; the inoculation part is detachably connected to the end, away from the container bottle, of the grinding shell, and a cavity of the inoculation part communicates with a cavity of the grinding shell; a culture dish convenient for inoculation is arranged in the inoculation part; the push rod assembly is used for pushing the ground tissue into the culture dish. The method has the effects of reducing the risk of high pollution and enabling the size of the ground tissue to be controllable.
Owner:ASIA STEM CELL BK CORP LTD

Device for simplifying the manual placenta removal procedure

PendingDE112024000256T5Ultrasonic/sonic/infrasonic diagnosticsStrain gaugeNatural childbirthAnatomy
The present invention relates to a device for simplifying the manual placenta removal procedure, which can be used to locate the placenta in the event that the placenta or the placental fragment remaining in the placenta, which does not spontaneously detach from the uterus after a natural birth, is removed by the manual placenta removal procedure, characterized in that it comprises;an elastic body (1) made of a flexible material, which is placed over the pregnant woman's abdomen immediately after birth, several strip sensors (2) on the surface of the elastic body (1) in contact with the patient's abdomen, which detect the density difference due to the tissue in the placenta, several warning LEDs (3) on the back of the elastic body (1), which, when the placenta is detected by the strip sensors (2), indicate the area corresponding to the placenta by flashing, and a control unit (4) which is connected to the elastic body (1) and controls and regulates the elastic body (1), the strip sensor (2) and the warning LED (3).
Owner:ISTANBUL GELISIM ÜNIVERSITESI AVCILAR

Genetically engineered placental mucosalassociated invariant t (MAIT) cells and uses thereof

This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.
Owner:PLURI BIOTECH LTD

Genetically engineered placental mucosalassociated invariant t (MAIT) cells and uses thereof

This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.
Owner:PLURI BIOTECH LTD

Methods of isolating cells from placental tissue

Methods for isolating a population of cells from tissue are disclosed herein. In particular, the present disclosure provides methods for isolating cytotrophoblasts from placental tissue. The methods include isolating a population of cells with the use of a laboratory apparatus that is coated with a lubricant, such as petroleum jelly. The methods described herein achieve consistent in vitro isolation of purified cells.
Owner:MEHARRY MEDICAL COLLEGE

Soluble placental ECM

The invention is directed to a composition of soluble placental ECM in storage solution and the methods of manufacture related thereto. The solubilized placental ECM solution is manufactured through a process of partitioning placental ECM from the placental tissue in a high acidic pH environment and performing an ultrafiltration step and diafiltration step through a tangential flow filtration system to increase the pH. The soluble placental ECM retains the native characteristics of placental ECM components and includes collagens (types I, III, V, VI, IX, and X), elastin, laminin, and fibronectin.
Owner:REGENTX PARTNERS LLC

A placental lipopolysaccharide preparation and preparation method thereof

The present invention relates to the technical field of lipopolysaccharide preparations, specifically, to a placental lipopolysaccharide preparation and a preparation method thereof, comprising the following components: 90-95 parts by weight of placental tissue, 1-5 parts by weight of sodium carbonate, 0.1-1 parts by weight of trypsin, 0.1-0.5 parts by weight of leupeptin, 1-2 parts by weight of chloroform, 0.1-1 parts by weight of chondroitin sulfate, 5-10 parts by weight of trichloroacetic acid, 70-80 parts by weight of methanol, 0.1-1 parts by weight of ascorbic acid and 0.5-1 parts by weight of sodium chloride. Since leupeptin can inhibit the activity of trypsin, it protects components such as proteins and peptides that have auxiliary effects on immunomodulation from being destroyed, thereby ensuring the quality and efficacy of the final preparation. Adding chondroitin sulfate can form a physical barrier or interact with lipopolysaccharide intermolecularly, thereby reducing the exposure of lipopolysaccharide in a complex chemical environment and preventing it from undergoing structural changes or loss of activity due to changes in the chemical environment.
Owner:YIGE PHARMA HUNAN PROV

Genetically engineered placental mucosalassociated invariant t (MAIT) cells and uses thereof

This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.
Owner:PLURI BIOTECH LTD

Methods of manufacture of therapeutic products comprising vitalized placental dispersions

PendingUS20250262245A1Peptide/protein ingredientsCulture processPlacental cellTrophoblast
This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.
Owner:OSIRIS THERAPEUTICS INC

A method for obtaining maternal-derived mesenchymal stem cells from the placenta

The present application discloses a method for obtaining maternal-derived mesenchymal stem cells from the placenta. The method for obtaining maternal-derived mesenchymal stem cells from the placenta in the present application includes obtaining placental tissue from a position within a radius of 5 cm from the umbilical cord in the placenta and more than 0.5 cm from the fetal surface; subjecting the placental tissue to enzymatic digestion treatment with an enzymatic digestion solution, and then culturing the product of the enzymatic digestion treatment to obtain maternal-derived mesenchymal stem cells. The method of the present application solves the technical problem of separating maternal-derived mesenchymal stem cells from the placenta. The prepared maternal-derived mesenchymal stem cells are large in quantity, high in purity, and not easily contaminated with neonatal cells, and can meet the clinical application requirements; the method of the present application solves the problems of low quantity of maternal-derived mesenchymal stem cells obtained from the decidua basalis and easy loss of the decidua basalis, and provides a new solution and approach for obtaining maternal-derived mesenchymal stem cells from the placenta.
Owner:SHENZHEN BGI CELL TECH CO LTD

Construction method of mouse placenta-targeted gene interference model and application thereof

PendingCN122250427AOvercome delivery limitationsHigh concentration enrichmentFermentationPlant genotype modificationDiseasePregnancy
The application discloses a kind of construction methods of mouse placenta targeted gene interference model and its application.The method comprises the following steps: first, pregnant mouse is anaesthetized and abdominal operation is carried out, and the uterus containing placenta is exposed;Then, the adeno-associated virus carrying gene interference element is directly injected into target placental tissue;Finally, the wound is sutured to complete model construction.The present application overcomes the problem of low virus delivery efficiency caused by maternal-fetal barrier by intraoperative direct site injection, and realizes the efficient and specific gene interference of placental tissue.The model constructed is targeted and precise, has high interference efficiency and low off-target effect, and provides an effective tool for studying placental gene function and pregnancy-related diseases.
Owner:EIGHTH AFFILIATED HOSPITAL SUN YAT SEN UNIV (SHENZHEN FUTIAN)

Application of overexpression hsaCLNS1A2 reagent in preparation of medicine for treating preeclampsia

The invention belongs to the technical field of biology, and particularly relates to application of a reagent for overexpressing hsaCLNS1A2 in preparation of a medicine for treating preeclampsia, the placenta tissues of a normal puerpera and a PE puerpera are sequenced by RNA sequencing, hsaCLNS1A2 is determined to be specific circRNA, and the influence of hsaCLNS1A2 on placental trophoblast pyroptosis and invasion and migration is clarified.
Owner:NINGXIA MEDICAL UNIV

Placenta active substance for promoting secretion of testosterone as well as preparation method and application of placenta active substance

The invention relates to a placenta active substance for promoting testosterone secretion as well as a preparation method and application of the placenta active substance. The preparation method comprises the following steps: carrying out crushing treatment on placenta tissues, mixing the crushed placenta tissues with protease and polysaccharide enzyme, carrying out enzymolysis, carrying out solid-liquid separation on an enzymolysis product, collecting clear liquid, and carrying out purification treatment on the clear liquid to obtain the placenta active factor. According to the novel placenta active substance preparation method, the mild, efficient and low-energy-consumption placenta active substance extraction process is achieved for the first time, the problems that in a traditional method, enzymolysis conditions are harsh, and active ingredients are easy to degrade are solved, and the obtained placenta active substances have high biological activity and high stability.
Owner:GUANGZHOU RUIBOYIN HEALTH TECH CO LTD

Fibrous birth tissue composition and method of use

A fibrous birth tissue composition fabricated from placental tissue is provided. Methods of processing a mammal's placental tissue to form a fibrous birth tissue composition are provided. Regenerative methods are also provided.
Owner:CONVATEC LTD

Method and composition for hypothermic storage of placental tissue

A tissue storage solution includes hypothermic storage compositions and methods. The hypothermic storage composition includes media containing Dulbecco's modified Eagle's medium (DMEM) and albumin. A method of hypothermically storing tissue includes storing such tissue in a storage medium including DMEM and albumin. A method for wound or defect treatment includes applying tissue, stored in a hypothermic storage medium containing DMEM and albumin, to the site of such wound or defect.
Owner:PRIME MERGER SUB LLC

Sterile human placental allografts having a plurality of slits, openings, and / or fenestrations formed thereon

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.
Owner:BIOSTEM TECHNOLOGIES INC

Sterile human placental allografts and methods of making thereof

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.
Owner:BIOSTEM TECHNOLOGIES INC